- Oops!Something went wrong.Please try again later.
Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact.
RGX-202 is designed to deliver optimized microdystrophin transgene with a unique C-terminal domain and a muscle-specific promoter to support targeted therapy for improved resistance to muscle damage associated with Duchenne.
RGX-202 uses RegenXbio's proprietary NAV AAV8 vector.
The Company expects to submit an Investigational New Drug (IND) application to the FDA for RGX-202 by the end of 2021.
Related content: Benzinga's Full FDA Calendar.
Price Action: RGNX shares are up 0.66% at $33.73 during the market session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.